gainbot
BriefMoversScreensSectorsEarningsIPOsNewsDividends & splitsScreenerWatchlistLearn
NASDAQ · ZLABHealthcarePharmaceuticals

Zai Lab Limited American Depositary Shares (ZLAB)

$26.04−1.44%
Close Nov 12, 2026 · split-adjusted
Nov 12, 2026$26.04▲ 19.01% in range
Nov 12, 2025Low $16.30 · High $27.00Nov 12, 2026
What changed · written from our data
As of Nov 12, 2026

Zai Lab Limited American Depositary Shares closed at $26.04 on Nov 12, down 1.44%, 3.6% below its 52-week closing high. Volume of 859.4K shares was 0.66× its 20-day average (below normal).

Split-adjusted performance: +15.7% over one month, +28.1% over six months, +18.4% over one year.

In the quarter ended Sep 30, 2026, revenue was $108.21M, down 6.8% from a year earlier, with a net margin of -42.6%.

Short interest was 8.1M shares at the Oct 30 settlement, down 8.5% from the prior report (6.7 days to cover).

Market cap$3.22B123.8M shares
Revenue · quarter$108.2M−6.8% YoY
Diluted EPS$-0.04—
P/E · TTM—P/S 7.3×
Net margin-42.6%Gross 52.6%
Dividend yieldNone
52-week range16.30 – 27.00−3.6% from high
Volume859.4K0.66× 20-day avg
Volatility · 60d55.2%Annualised
Short % of float—6.7 days to cover
Net cash$307.3MCash $559.7M
Next earnings—Not scheduled
Split-adjusted performance
1W +15.2%1M +15.7%3M +0.5%6M +28.1%YTD +47.6%1Y +18.4%3Y −8.0%5Y −74.7%

Earnings reactions

History →

No reported quarters with price history yet.

Rank within Pharmaceuticals

Percentile among 417 companies (100 = best)

6-month momentum—
Revenue growth—
Net margin—
Value (low P/E)—
Size—

Industry medians: 6-month return −26.3%, revenue growth +9.3%, net margin −35.1%, P/E 16.5×.

Short interest

Details →
Shares short8.1M−8.5% vs prior
Days to cover6.7Settled Oct 30
% of float—
Short vol. 10d48.0%of daily volume

Closest peers by size in Pharmaceuticals

CompanyPriceToday6MRev. growthNet marginP/EMkt cap
ZLABZai Lab Limited$26.04−1.44%+28.1%−6.8%−42.6%—$3.22B
GPCRStructure Therapeutics$19.84−5.30%−50.2%———$1.41BCompare
CMPSCOMPASS Pathways Plc American Depository Shares$9.12−1.94%−14.1%———$1.29BCompare
SLNSilence Therapeutics Plc American Depository Share$19.80+0.15%+177.7%———$1.23BCompare
AMRNAmarin$11.67−0.34%−21.0%−20.4%0.6%—$490.6MCompare
BCYCBicycle Therapeutics$3.45−6.50%−26.1%+190.2%−30.8%—$241.8MCompare
ONCBeOne Medicines$415.96−0.96%+36.6%+33.8%20.4%51.9$47.51BCompare
KZIAKazia Therapeutics Limited$6.95−6.46%−49.7%———$108.1MCompare
MREOMereo BioPharma Group$0.3050−0.52%+24.0%———$48.7MCompare

News about Zai Lab Limited

All news →
Boehringer Ingelheim and Zai Lab announce Collaboration on DLL3‑targeting T‑Cell Engager and ADC Combination in Small Cell Lung Cancer and Other Neuroendocrine CarcinomasGlobeNewswire Inc. · Apr 15, 2026▲ Positive

Quick answers

What does Zai Lab Limited American Depositary Shares do?
Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. Zai Lab has a diverse pipeline of potentially first-in-class product candidates developed through in-house R&D and global partnerships.
What is ZLAB's market cap?
$3.22B, based on the Nov 12 close of $26.04.
What sector is ZLAB in?
Healthcare, in the Pharmaceuticals industry.

About Zai Lab Limited

Zai Lab Ltd is a biopharmaceutical company focusing on discovering or licensing, developing, and commercializing proprietary therapeutics that address areas of unmet medical need including in the fields of oncology, autoimmune and infectious diseases. Zai Lab has a diverse pipeline of potentially first-in-class product candidates developed through in-house R&D and global partnerships. The company has successfully commercialized several products in China, including Zejula, Optune, Qinlock, and Nuzyra, with plans for further expansion The pipeline of proprietary drug candidates of the company includes ZL-1222, ZL-1311, ZL-6201 and many others.

HQ: Shanghai, 1,797 employeesListed Sep 20, 2017zailaboratory.com

Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology